Sign in

CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
813879991
Phone
617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Open-market sale Chief Scientific Officer sold 1,145 shares at $8.50 ($9,733)
  2. 4 Open-market sale Chief Medical Officer sold 386 shares at $8.22 ($3,173)
  3. 4 Open-market sale Chief Scientific Officer sold 238 shares at $8.22 ($1,956)
  4. 4 Open-market sale Chief Legal Officer sold 290 shares at $8.22 ($2,384)
  5. 4 Open-market sale Chief Financial Officer sold 398 shares at $8.22 ($3,272)
  6. 4 Open-market sale Chief Financial Officer sold 1,926 shares at $7.81 ($15,042)
  7. 4 Open-market sale Chief Scientific Officer sold 1,068 shares at $7.81 ($8,341)
  8. 10-Q Report Quarterly Report
  9. 8-K Event Results of operations
  10. SC 13G/A Stake Amended Statement of Ownership
  11. 10-Q Report Quarterly Report
  12. 8-K Event Results of operations
  13. 4 Grant or award Chief Financial Officer acquired 2,340 shares (grant or award)
  14. 4 Open-market sale President and CEO sold 759 shares at $11.40 ($8,653)
  15. 4 Open-market sale Chief Medical Officer sold 387 shares at $12.94 ($5,008)
  16. 4 Open-market sale Chief Development Officer sold 238 shares at $12.94 ($3,080)
  17. 4 Open-market sale Chief Financial Officer sold 399 shares at $12.94 ($5,163)
  18. 4 Open-market sale Chief Legal Officer sold 291 shares at $12.94 ($3,766)
  19. 4 Open-market sale Chief Financial Officer sold 319 shares at $13.11 ($4,182)
  20. 4 Open-market sale Chief Development Officer sold 176 shares at $13.11 ($2,307)

Page 12 of 24 · 471 filings